• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists


News provided by

Reportlinker

Mar 06, 2012, 09:56 ET

Share this article

Share this article


NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists

http://www.reportlinker.com/p0789007/Diabetes-Therapeutics-Market-to-2017---Better-Glycemic-Control-and-Reduced-Potential-Risk-of-Hypoglycemia-to-Increase-the-Market-Share-of-DPP-IV-Inhibitors-and-GLP-1-Agonists.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists" which provides insights into diabetes therapeutics sales and price forecasts until 2017. The report also examines the global diabetes therapies' treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region, and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of the two diabetes therapeutic indications, which are Type 1 and Type 2 diabetes. In addition, it includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

The global diabetes market is growing rapidly due to the increasing diabetes population in the developed countries of the US, the UK and Germany. In 2010, the global diabetes market was estimated at $29.3 billion, representing a compound annual growth rate (CAGR) of 10.0% between 2003 and 2010. The diabetes Type 2 market, with sales worth $21.0 billion in 2010, accounted for 72% of the total diabetes market. Insulin analogues dominated the market, followed by oral hypoglycemic agents. By 2017, the global diabetes therapeutics market is forecast to record $47.2 billion, representing a CAGR of 7.1% between 2010 and 2017. The Type 1 diabetes market is expected to account for $13.2 billion, and the Type 2 diabetes market is expected to account for $34.0 billion in 2017.

GBI Research finds that the global diabetes therapeutics market is dominated by Novo Nordisk, Sanofi and Takeda, which contribute almost 60% of the market share in the global diabetes market. The competitive landscape in the market is set to change due to the success of recent launches and the potential success of new drugs that will be launched during the period 2010-2017. The market will also be impacted by the decline in the sales of leading products such as GlaxoSmithKline's Avandia and Takeda's Actos.

GBI Research estimates that the market share of Eli Lilly and Merck in the diabetes market will increase due to the potential success of Teplizumab, which is in Phase III, and Januvia, which was launched in 2006. In addition, Novo Nordisk's Victoza is expected to give tough competition to Merck's Januvia and is expected to generate sales of $1.4 billion by 2014.

Scope

- Data and analysis on the diabetes therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the diabetes therapeutics market from 2003 to 2010, with forecasts to 2017 for Type 1 and Type 2 diabetes.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as prevalence population, treatment seeking population, diagnosed population and prescription population.

- Key drivers and restraints that have had a significant impact on the market.

- Market share analysis of the top companies and the drug classes in 2010 and their forecasts in 2017.

- Competitive landscape of the global diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Eli Lilly, Merck, GlaxoSmithKline and Amylin Pharmaceuticals.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that can fill their portfolio gaps.

- Align the product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Diabetes Therapeutics Market to 2017 - Introduction 11

2.1 GBI Research Report Guidance 12

3 Diabetes Therapeutics Market to 2017 - Market Overview 13

3.1 Introduction 13

3.2 Three Major Unmet Needs Prevalent in the Diabetes Market 13

3.2.1 Complications like Heart Risks are Associated with Some of the Oral Anti-Diabetic Drugs 13

3.2.2 Patients on Insulin Analogues are Prone to Carcinogenic Effects 14

3.2.3 Poor Patient Compliance with Anti-Diabetic Drug Therapy 14

3.3 Revenue 15

3.4 Annual Cost of Therapy (ACT) 17

3.5 Treatment Usage Patterns 19

3.5.1 Prevalence Population 21

3.5.2 Treatment Seeking Population 22

3.5.3 Diagnosed Population 23

3.5.4 Prescription Population 24

3.6 Drivers and Restraints of the Diabetes Therapeutics Market 25

3.6.1 Drivers of the Diabetes Market 25

3.6.2 Restraints for the Diabetes Market 26

3.7 Branded vs. Generic Market Share in the Global Diabetes Market 27

4 Diabetes Therapeutics Market to 2017 - Geographical Landscape 28

4.1 The US 28

4.1.1 Revenue 28

4.1.2 Annual Cost of Therapy 30

4.1.3 Treatment Usage Patterns 31

4.2 Top Five Countries of Europe 37

4.2.1 Revenue 37

4.2.2 Annual Cost of Therapy 39

4.2.3 Treatment Usage Patterns 40

4.3 Japan 46

4.3.1 Revenue 46

4.3.2 Annual Cost of Therapy 47

4.3.3 Treatment Usage Patterns 48

5 Diabetes Therapeutics Market to 2017 - Therapeutic Landscape 53

5.1 Type 1 Diabetes Market 53

5.1.1 Introduction 53

5.1.2 Symptoms 53

5.1.3 Treatment 53

5.1.4 Unmet Needs 55

5.1.5 Branded vs. Generic Market Share in the Type 1 Diabetes Market 56

5.1.6 Revenue 57

5.1.7 Annual Cost of Therapy (ACT) 58

5.1.8 Treatment Flow Algorithm for Type 1 Diabetes 60

5.1.9 Treatment Usage Patterns 61

5.1.10 Drivers and Restraints for the Type 1 Diabetes Market 66

5.2 Type 2 Diabetes Market 68

5.2.1 Introduction 68

5.2.2 Symptoms 68

5.2.3 Treatment 68

5.2.4 Unmet Needs 68

5.2.5 Branded vs. Generic Market Share in the Type 2 Diabetes Market 70

5.2.6 Revenue 70

5.2.7 Annual Cost of Therapy 72

5.2.8 Treatment Flow Algorithm for Type 2 Diabetes 73

5.2.9 Treatment Usage Patterns 74

5.2.10 Drivers and Restraints for the Type 2 Diabetes Market 79

6 Diabetes Therapeutics Market to 2017 - Pipeline Analysis 81

6.1 Introduction 81

6.1.1 Research and Development Pipeline - Type 1 Diabetes 82

6.1.2 Research and Development Pipeline - Type 2 Diabetes 89

6.2 Innovations in Diabetes Treatment 100

6.2.1 Insulin in Pills (Oral Delivery) 100

6.2.2 Promising Treatments for Diabetic Retinopathy 100

6.2.3 Biomarkers in Diabetes 100

6.2.4 Combination Drugs are an Important Part of the Diabetes Pipeline 101

6.2.5 Cellular Activation Therapy (CAT) 101

6.3 Drug Delivery in Diabetes 102

6.3.1 Factors Determining Preference for Drug Delivery 102

6.3.2 Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable 102

6.3.3 Innovation in Drug Delivery Systems 102

6.4 Profiles of Promising Drugs in the Diabetes Market 104

6.4.1 rhGAD65 (Diamyd) 104

6.4.2 Bydureon 104

6.4.3 DiaPep277 105

6.4.4 Otelixizumab 106

6.4.5 Alogliptin 106

6.4.6 Oral-Lyn 107

6.4.7 Dapagliflozin 108

6.4.8 Canagliflozin 109

6.4.9 MB07803 110

7 Diabetes Therapeutics Market to 2017 - Competitive Landscape 111

7.1 Diabetes Market Overview 111

7.1.1 Human Insulin Products and Oral Antidiabetic Drugs like Actos Group (Actos and Actoplus Met) and Lantus Have Led Market Growth 111

7.2 Market Share Analysis - Diabetes 112

7.2.1 Market Share Analysis by Company - 2010 112

7.2.2 Market Share Analysis by Company - 2017 113

7.3 Market Share Analysis by Class for the Anti-Diabetic Drugs 114

7.3.1 Market Share Analysis by Drug Class - 2010 114

7.3.2 Market Share Analysis by Drug Class - 2017 115

7.4 Competitive Profiling 116

7.4.1 Novo Nordisk 116

7.4.2 Sanofi 121

7.4.3 Takeda 126

7.4.4 Eli Lilly 129

7.4.5 GlaxoSmithKline (GSK) 135

7.4.6 Merck & Co Inc 139

7.4.7 Amylin Pharmaceuticals 142

8 Diabetes Therapeutics Market to 2017 - M&A Landscape 146

8.1 Overview 146

8.2 Mergers and Acquisitions (M&A) 148

8.2.1 Strategic Consolidation 148

8.2.2 M&A Deals by Value 149

8.2.3 Major Mergers and Acquisitions 150

8.2.4 M&A Deals by Geography 151

8.2.5 M&A Deals by Indication 152

8.3 Licensing Agreements 153

8.3.1 Licensing by Geography 153

8.3.2 Major Licensing Agreements 154

8.3.3 Licensing Agreements by Indication 156

8.3.4 Licensing Agreements by Value 157

8.4 Co-Development 158

8.4.1 Co-Development by Geography 158

8.4.2 Major Co-Development Deals 159

8.4.3 Co-Development by Indication 161

8.4.4 Co-Development by Value 162

9 Diabetes Therapeutics Market to 2017 - Appendix 163

9.1 Market Definitions 163

9.2 Abbreviations 163

9.3 Research Methodology 163

9.3.1 Coverage 164

9.3.2 Secondary Research 164

9.3.3 Primary Research 165

9.3.4 Forecasts 165

9.3.5 Expert Panel Validation 167

9.4 Contact Us 168

9.5 Disclaimer 168

9.6 Sources 168

1.1 List of Tables

Table 1: Diabetes Therapeutics Market, Global, Revenue ($bn), 2003-2010 16

Table 2: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 16

Table 3: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2010 18

Table 4: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 18

Table 5: Diabetes Therapeutics Market, Global, Treatment Usage Patterns (millions), 2003-2010 19

Table 6: Diabetes Therapeutics Market, The US, Revenue ($bn), 2003-2010 29

Table 7: Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 29

Table 8: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2010 30

Table 9: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 30

Table 10: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2003-2010 31

Table 11: Diabetes Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017 32

Table 12: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue, $bn, 2003-2010 38

Table 13: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2010-2017 38

Table 14: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2010 39

Table 15: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 39

Table 16: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2003-2010 40

Table 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2017 41

Table 18: Diabetes Therapeutics Market, Japan, Revenues ($bn), 2003-2010 46

Table 19: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 46

Table 20: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2010 47

Table 21: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 47

Table 22: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2003-2010 48

Table 23: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017 48

Table 24: Diabetes Therapeutics Market, Type 1 Diabetes Market, Types of Insulin Regimen 54

Table 25: Type 1 Diabetes Market, Global, Revenues ($bn), 2003-2010 57

Table 26: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017 57

Table 27: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010 58

Table 28: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017 59

Table 29: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010 61

Table 30: Type 1 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017 61

Table 31: Type 2 Diabetes Market, Global, Revenues ($bn), 2003-2010 71

Table 32: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2010-2017 71

Table 33: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2010 72

Table 34: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2010-2017 72

Table 35: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2003-2010 74

Table 36: Type 2 Diabetes Market, Global, Treatment Usage Patterns (millions), 2010-2017 74

Table 37: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011 82

Table 38: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Pre-Clinical, 2011 83

Table 39: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011 84

Table 40: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011 85

Table 41: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011 88

Table 42: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011 88

Table 43: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Discovery, 2011 90

Table 44: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, IND Filed, 2011 91

Table 45: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase I, 2011 91

Table 46: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase II, 2011 94

Table 47: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, Phase III, 2011 98

Table 48: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase, NDA Filed, 2011 99

Table 49: Diabetes Therapeutics Market, Factors Determining Preference of Drug Delivery in Diabetes 101

Table 50: Diabetes Therapeutics Market, Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable 102

Table 51: Diabetes Therapeutics Market, Novo Nordisk, Pipeline Products, 2011 120

Table 52: Diabetes Therapeutics Market, Sanofi, Pipeline Products, 2011 125

Table 53: Diabetes Therapeutics Market, Takeda, Pipeline Products, 2011 128

Table 54: Diabetes Therapeutics Market, Eli Lilly, Pipeline Products, 2011 134

Table 55: Diabetes Therapeutics Market, GSK, Pipeline Products, 2011 138

Table 56: Diabetes Therapeutics Market, Merck, Pipeline Products, 2011 141

Table 57: Diabetes Therapeutics Market, Amylin, Pipeline Products (%), 2010 144

Table 58: Diabetes Therapeutics Market, Global, Strategic Consolidation, 2004-2011 148

Table 59: Diabetes Therapeutics Market, Global, Number of M&A Deals by Value, 2004-2011 149

Table 60: Diabetes Therapeutics Market, Global, Mergers and Acquisitions, 2010-2011 150

Table 61: Diabetes Therapeutics Market, Global, Number of M&A Deals by Geography, 2004-2011 151

Table 62: Diabetes Therapeutics Market, Global, Number of M&A Deals by Indication, 2004-2011 152

Table 63: Diabetes Therapeutics Market, Global, Number of Licensing Agreements by Geography, 2004-2011 153

Table 64: Diabetes Therapeutics Market, Global, Licensing Agreements, 2010-2011 154

Table 65: Diabetes Therapeutics Market to 2017, Global, Number of Licensing Agreements by Indication, 2004-2011 156

Table 66: Diabetes Therapeutics Market to 2017, Number of Licensing Agreements by Value, Global, 2004-2011 157

Table 67: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Geography, 2004-2011 158

Table 68: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals, 2010-2011 159

Table 69: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication, 2004-2011 161

Table 70: Diabetes Therapeutics Market to 2017, Global, Number of Co-Development Deals by Value, 2004-2011 162

1.2 List of Figures

Figure 1: Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2017 15

Figure 2: Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2017 17

Figure 3: Diabetes Therapeutics Market, Global, Treatment Usage Patterns, 2003-2017 19

Figure 4: Diabetes Therapeutics Market, Global, Prevalence Population, 2003-2017 21

Figure 5: Diabetes Therapeutics Market, Global, Treatment Seeking Population, 2003-2017 22

Figure 6: Diabetes Therapeutics Market, Global, Diagnosed Population, 2003-2017 23

Figure 7: Diabetes Therapeutics Market, Global, Prescription Population, 2003-2017 24

Figure 8: Diabetes Therapeutics Market, Global, Drivers and Restraints 25

Figure 9: Diabetes Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2010 27

Figure 10: Diabetes Therapeutics Market, The US, Revenue Forecasts, ($bn), 2003-2017 28

Figure 11: Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2017 30

Figure 12: Diabetes Therapeutics Market, The US, Treatment Usage Patterns, 2003-2017 31

Figure 13: Diabetes Therapeutics Market, The US, Prevalence Population, 2003-2017 33

Figure 14: Diabetes Therapeutics Market, The US, Treatment Seeking Population, 2003-2017 34

Figure 15: Diabetes Therapeutics Market, The US, Diagnosed Population, 2003-2017 35

Figure 16: Diabetes Therapeutics Market, The US, Prescription Population, 2003-2017 36

Figure 17: Diabetes Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, $bn, 2003-2017 37

Figure 18: Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2017 39

Figure 19: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2003-2017 40

Figure 20: Diabetes Therapeutics Market, Top Five Countries of Europe, Prevalence Population, 2003-2017 42

Figure 21: Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population, 2003-2017 43

Figure 22: Diabetes Therapeutics Market, Top Five Countries of Europe, Diagnosed Population, 2003-2017 44

Figure 23: Diabetes Therapeutics Market, Top Five Countries of Europe, Prescription Population, 2003-2017 45

Figure 24: Diabetes Therapeutics Market, Japan, Revenue Forecasts ($bn), 2003-2017 46

Figure 25: Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2017 47

Figure 26: Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2003-2017 48

Figure 27: Diabetes Therapeutics Market, Japan, Prevalence Population, 2003-2017 49

Figure 28: Diabetes Therapeutics Market, Japan, Treatment Seeking Population, 2003-2017 50

Figure 29: Diabetes Therapeutics Market, Japan, Diagnosed Population, 2003-2017 51

Figure 30: Diabetes Therapeutics Market, Japan, Prescription Population, 2003-2017 52

Figure 31: Type 1 Diabetes Market, Global, Unmet Needs 55

Figure 32: Type 1 Diabetes Market, Global, Branded vs. Generic Market Share (%), 2010 56

Figure 33: Type 1 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017 57

Figure 34: Type 1 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017 58

Figure 35: Type 1 Diabetes Market, Global, Treatment Flow Algorithm 60

Figure 36: Type 1 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017 61

Figure 37: Type 1 Diabetes Market, Global, Prevalence Population, 2003-2017 62

Figure 38: Type 1 Diabetes Market, Global, Treatment Seeking Population, 2003-2017 63

Figure 39: Type 1 Diabetes Market, Global, Diagnosed Population, 2003-2017 64

Figure 40: Type 1 Diabetes Market, Global, Prescription Population, 2003-2017 65

Figure 41: Type 1 Diabetes Market, Global, Diabetes Market Drivers and Restraints 67

Figure 42: Type 2 Diabetes Market, Global, Unmet Needs 69

Figure 43: Type 2 Diabetes Market, Global, Branded vs Generic Market Share, 2010 70

Figure 44: Type 2 Diabetes Market, Global, Revenue Forecasts ($bn), 2003-2017 71

Figure 45: Type 2 Diabetes Market, Global, Annual Cost of Therapy ($), 2003-2017 72

Figure 46: Type 2 Diabetes Market, Global, Treatment Flow Algorithm 73

Figure 47: Type 2 Diabetes Market, Global, Treatment Usage Patterns, 2003-2017 74

Figure 48: Type 2 Diabetes Market, Global, Prevalence Population, 2003-2017 75

Figure 49: Type 2 Diabetes Market, Global, Treatment Seeking Population, 2003-2017 76

Figure 50: Type 2 Diabetes Market, Global, Diagnosed Population, 2003-2017 77

Figure 51: Type 2 Diabetes Market, Global, Prescription Population, 2003-2017 78

Figure 52: Type 2 Diabetes Market, Global, Market Drivers and Restraints, 2010-2017 79

Figure 53: Diabetes Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 81

Figure 54: Type 1 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 82

Figure 55: Type 2 Diabetes Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011, 89

Figure 56: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2010 112

Figure 57: Diabetes Therapeutics Market, Global, Market Share by Company (%), 2017 113

Figure 58: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2010 114

Figure 59: Diabetes Therapeutics Market, Global, Market Share by Drug Class (%), 2017 115

Figure 60: Diabetes Therapeutics Market, Novo Nordisk, Revenue by Segment (%), 2010 116

Figure 61: Diabetes Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product (%), 2010 117

Figure 62: Diabetes Therapeutics Market, SWOT Analysis, Novo Nordisk 120

Figure 63: Diabetes Therapeutics Market, Sanofi, Revenue by Segment (%), 2010 121

Figure 64: Diabetes Therapeutics Market, Sanofi, Diabetes Revenue by Product (%), 2010 122

Figure 65: Diabetes Therapeutics Market, SWOT Analysis, Sanofi 125

Figure 66: Diabetes Therapeutics Market, Takeda, Revenue by Segment (%), 2010 126

Figure 67: Diabetes Therapeutics Market, SWOT Analysis, Takeda 128

Figure 68: Diabetes Therapeutics Market, Eli Lilly, Revenue by Segment (%), 2010 129

Figure 69: Diabetes Therapeutics Market, Eli Lilly, Diabetes Revenue by Product (%), 2010 130

Figure 70: Diabetes Therapeutics Market, SWOT Analysis, Eli Lilly 134

Figure 71: Diabetes Therapeutics Market, GSK, Revenue by Segment (%), 2010 135

Figure 72: Diabetes Therapeutics Market, SWOT Analysis, GSK 138

Figure 73: Diabetes Therapeutics Market, Merck, Revenue by Segment, 2010 139

Figure 74: Diabetes Therapeutics Market, SWOT Analysis, Merck 141

Figure 75: Diabetes Therapeutics Market, Amylin, Revenue by Segment (%), 2010 142

Figure 76: Diabetes Therapeutics Market, Amylin, Diabetes Revenue by Product (%), 2010 143

Figure 77: Diabetes Therapeutics Market, SWOT Analysis, Amylin 145

Figure 78: Diabetes Therapeutics Market, Global, Strategic Consolidation (%), 2004-2011 148

Figure 79: Diabetes Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011 149

Figure 80: Diabetes Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011 151

Figure 81: Diabetes Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2011 152

Figure 82: Diabetes Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011 153

Figure 83: Diabetes Therapeutics Market, Global, Licensing Agreements by Indication (%), 2004-2011 156

Figure 84: Diabetes Therapeutics Market to 2017, Global, Licensing Agreements by Value (%), 2004-2011 157

Figure 85: Diabetes Therapeutics Market to 2017, Global, Co-Development by Geography (%), 2004-2011 158

Figure 86: Diabetes Therapeutics Market to 2017, Global, Co-Development by Indication (%), 2004-2011 161

Figure 87: Diabetes Therapeutics Market to 2017, Global, Co-Development Deals by Value (%), 2004-2011 162

Figure 88: Diabetes Therapeutics Market, GBI Research Market Forecasting Model 167

Companies mentioned

Novo Nordisk

Sanofi

Takeda

Eli Lilly

GlaxoSmithKline (GSK)

Merck & Co Inc

Amylin Pharmaceuticals

To order this report:

Therapy Industry: Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.